BioCentury
ARTICLE | Clinical News

Cebix preclinical data

July 4, 2011 7:00 AM UTC

In a rat model of diabetic peripheral neuropathy, subcutaneous Ersatta led to a 4 m/sec reversal of sensory nerve conduction velocity impairment. The long-acting form of C-peptide is in Phase Ib testi...